Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.40
$0.020.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -1.31% | |||
| Gross Profit | -- | 1.31% | |||
| SG&A Expenses | -1.73% | -2.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.29% | -1.70% | |||
| Operating Income | 18.29% | 1.70% | |||
| Income Before Tax | 18.11% | 0.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.11% | 0.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.11% | 0.47% | |||
| EBIT | 18.29% | 1.70% | |||
| EBITDA | 18.47% | 1.72% | |||
| EPS Basic | 59.09% | -98.96% | |||
| Normalized Basic EPS | 59.11% | -99.08% | |||
| EPS Diluted | 59.09% | -98.96% | |||
| Normalized Diluted EPS | 59.11% | -99.08% | |||
| Average Basic Shares Outstanding | 0.08% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||